These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 20812236)
1. Targeting of LcrV virulence protein from Yersinia pestis to dendritic cells protects mice against pneumonic plague. Do Y; Koh H; Park CG; Dudziak D; Seo P; Mehandru S; Choi JH; Cheong C; Park S; Perlin DS; Powell BS; Steinman RM Eur J Immunol; 2010 Oct; 40(10):2791-6. PubMed ID: 20812236 [TBL] [Abstract][Full Text] [Related]
2. Intranasal delivery of a protein subunit vaccine using a Tobacco Mosaic Virus platform protects against pneumonic plague. Arnaboldi PM; Sambir M; D'Arco C; Peters LA; Seegers JF; Mayer L; McCormick AA; Dattwyler RJ Vaccine; 2016 Nov; 34(47):5768-5776. PubMed ID: 27745954 [TBL] [Abstract][Full Text] [Related]
3. Induction of pulmonary mucosal immune responses with a protein vaccine targeted to the DEC-205/CD205 receptor. Do Y; Didierlaurent AM; Ryu S; Koh H; Park CG; Park S; Perlin DS; Powell BS; Steinman RM Vaccine; 2012 Oct; 30(45):6359-67. PubMed ID: 22947140 [TBL] [Abstract][Full Text] [Related]
4. TNFα and IFNγ contribute to F1/LcrV-targeted immune defense in mouse models of fully virulent pneumonic plague. Lin JS; Park S; Adamovicz JJ; Hill J; Bliska JB; Cote CK; Perlin DS; Amemiya K; Smiley ST Vaccine; 2010 Dec; 29(2):357-62. PubMed ID: 20840834 [TBL] [Abstract][Full Text] [Related]
5. A Recombinant Attenuated Singh AK; Curtiss R; Sun W Infect Immun; 2019 Oct; 87(10):. PubMed ID: 31331960 [TBL] [Abstract][Full Text] [Related]
6. Combinatorial Viral Vector-Based and Live Attenuated Vaccines without an Adjuvant to Generate Broader Immune Responses to Effectively Combat Pneumonic Plague. Kilgore PB; Sha J; Hendrix EK; Motin VL; Chopra AK mBio; 2021 Dec; 12(6):e0322321. PubMed ID: 34872353 [TBL] [Abstract][Full Text] [Related]
7. Broad T cell immunity to the LcrV virulence protein is induced by targeted delivery to DEC-205/CD205-positive mouse dendritic cells. Do Y; Park CG; Kang YS; Park SH; Lynch RM; Lee H; Powell BS; Steinman RM Eur J Immunol; 2008 Jan; 38(1):20-9. PubMed ID: 18081041 [TBL] [Abstract][Full Text] [Related]
8. Delivery of Tong Z; Zhang X; Guo X; Wu G; Cao S; Zhang Y; Meng X; Wang T; Wang Y; Song Y; Yang R; Du Z mSphere; 2024 Sep; 9(9):e0033024. PubMed ID: 39158304 [TBL] [Abstract][Full Text] [Related]
9. Neutralization of Yersinia pestis-mediated macrophage cytotoxicity by anti-LcrV antibodies and its correlation with protective immunity in a mouse model of bubonic plague. Zauberman A; Cohen S; Levy Y; Halperin G; Lazar S; Velan B; Shafferman A; Flashner Y; Mamroud E Vaccine; 2008 Mar; 26(13):1616-25. PubMed ID: 18304706 [TBL] [Abstract][Full Text] [Related]
10. Robust Th1 cellular and humoral responses generated by the Yersinia pestis rF1-V subunit vaccine formulated to contain an agonist of the CD137 pathway do not translate into increased protection against pneumonic plague. Bowen W; Batra L; Pulsifer AR; Yolcu ES; Lawrenz MB; Shirwan H Vaccine; 2019 Sep; 37(38):5708-5716. PubMed ID: 31416643 [TBL] [Abstract][Full Text] [Related]
11. Polymorphisms in the lcrV gene of Yersinia enterocolitica and their effect on plague protective immunity. Miller NC; Quenee LE; Elli D; Ciletti NA; Schneewind O Infect Immun; 2012 Apr; 80(4):1572-82. PubMed ID: 22252870 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of protective potential of Yersinia pestis outer membrane protein antigens as possible candidates for a new-generation recombinant plague vaccine. Erova TE; Rosenzweig JA; Sha J; Suarez G; Sierra JC; Kirtley ML; van Lier CJ; Telepnev MV; Motin VL; Chopra AK Clin Vaccine Immunol; 2013 Feb; 20(2):227-38. PubMed ID: 23239803 [TBL] [Abstract][Full Text] [Related]
13. Involvement of CD8+ T cell-mediated immune responses in LcrV DNA vaccine induced protection against lethal Yersinia pestis challenge. Wang S; Goguen JD; Li F; Lu S Vaccine; 2011 Sep; 29(39):6802-9. PubMed ID: 21199697 [TBL] [Abstract][Full Text] [Related]
14. Humoral and cellular immune correlates of protection against bubonic plague by a live Yersinia pseudotuberculosis vaccine. Demeure CE; Derbise A; Guillas C; Gerke C; Cauchemez S; Carniel E; Pizarro-Cerdá J Vaccine; 2019 Jan; 37(1):123-129. PubMed ID: 30467064 [TBL] [Abstract][Full Text] [Related]
15. Yersinia pestis caf1 variants and the limits of plague vaccine protection. Quenee LE; Cornelius CA; Ciletti NA; Elli D; Schneewind O Infect Immun; 2008 May; 76(5):2025-36. PubMed ID: 18347051 [TBL] [Abstract][Full Text] [Related]
16. Vaccine Potential of a Recombinant Bivalent Fusion Protein LcrV-HSP70 Against Plague and Yersiniosis. Gupta A; Narayan B; Kumar S; Verma SK Front Immunol; 2020; 11():988. PubMed ID: 32595634 [TBL] [Abstract][Full Text] [Related]
18. Complete Protection against Pneumonic and Bubonic Plague after a Single Oral Vaccination. Derbise A; Hanada Y; Khalifé M; Carniel E; Demeure CE PLoS Negl Trop Dis; 2015; 9(10):e0004162. PubMed ID: 26473734 [TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and protective immunity against bubonic plague and pneumonic plague by immunization of mice with the recombinant V10 antigen, a variant of LcrV. DeBord KL; Anderson DM; Marketon MM; Overheim KA; DePaolo RW; Ciletti NA; Jabri B; Schneewind O Infect Immun; 2006 Aug; 74(8):4910-4. PubMed ID: 16861680 [TBL] [Abstract][Full Text] [Related]
20. Concomitant administration of Yersinia pestis specific monoclonal antibodies with plague vaccine has a detrimental effect on vaccine mediated immunity. Eyles JE; Butcher WA; Titball RW; Hill J Vaccine; 2007 Oct; 25(42):7301-6. PubMed ID: 17869388 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]